Validation of the WATCH-DM and TRS-HF DM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis.
Matthew W SegarKershaw V PatelAnne S HellkampMuthiah VaduganathanYuliya LokhnyginaJennifer B GreenSiu-Hin WanAhmed A KolkailahRury R HolmanEric D PetersonVaishnavi KannanDuwayne L WillettDarren K McGuireAmbarish PandeyPublished in: Journal of the American Heart Association (2022)
Background The WATCH-DM (weight [body mass index], age, hypertension, creatinine, high-density lipoprotein cholesterol, diabetes control [fasting plasma glucose], ECG QRS duration, myocardial infarction, and coronary artery bypass grafting) and TRS-HF DM (Thrombolysis in Myocardial Infarction [TIMI] risk score for heart failure in diabetes) risk scores were developed to predict risk of heart failure (HF) among individuals with type 2 diabetes. WATCH-DM was developed to predict incident HF, whereas TRS-HF DM predicts HF hospitalization among patients with and without a prior HF history. We evaluated the model performance of both scores to predict incident HF events among patients with type 2 diabetes and no history of HF hospitalization across different cohorts and clinical settings with varying baseline risk. Methods and Results Incident HF risk was estimated by the integer-based WATCH-DM and TRS-HF DM scores in participants with type 2 diabetes free of baseline HF from 2 randomized clinical trials (TECOS [Trial Evaluating Cardiovascular Outcomes With Sitagliptin], N=12 028; and Look AHEAD [Look Action for Health in Diabetes] trial, N=4867). The integer-based WATCH-DM score was also validated in electronic health record data from a single large health care system (N=7475). Model discrimination was assessed by the Harrell concordance index and calibration by the Greenwood-Nam-D'Agostino statistic. HF incidence rate was 7.5, 3.9, and 4.1 per 1000 person-years in the TECOS, Look AHEAD trial, and electronic health record cohorts, respectively. Integer-based WATCH-DM and TRS-HF DM scores had similar discrimination and calibration for predicting 5-year HF risk in the Look AHEAD trial cohort (concordance indexes=0.70; Greenwood-Nam-D'Agostino P >0.30 for both). Both scores had lower discrimination and underpredicted HF risk in the TECOS cohort (concordance indexes=0.65 and 0.66, respectively; Greenwood-Nam-D'Agostino P <0.001 for both). In the electronic health record cohort, the integer-based WATCH-DM score demonstrated a concordance index of 0.73 with adequate calibration (Greenwood-Nam-D'Agostino P =0.96). TRS-HF DM score could not be validated in the electronic health record because of unavailability of data on urine albumin/creatinine ratio in most patients in the contemporary clinical practice. Conclusions The WATCH-DM and TRS-HF DM risk scores can discriminate risk of HF among intermediate-risk populations with type 2 diabetes.
Keyphrases
- electronic health record
- acute heart failure
- heart failure
- glycemic control
- cardiovascular disease
- body mass index
- type diabetes
- clinical decision support
- coronary artery bypass grafting
- clinical trial
- blood pressure
- clinical practice
- healthcare
- blood glucose
- randomized controlled trial
- machine learning
- ejection fraction
- phase ii
- atrial fibrillation
- percutaneous coronary intervention
- metabolic syndrome
- acute coronary syndrome
- risk assessment
- climate change
- heart rate
- big data
- low cost
- genetic diversity